Ahmed Salah, Mohammed El-Desuky, Amal Rizk, Amr El-Hadidy
{"title":"阿司匹林抵抗:在埃及的流行和临床结果","authors":"Ahmed Salah, Mohammed El-Desuky, Amal Rizk, Amr El-Hadidy","doi":"10.1016/j.ejccm.2014.12.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The antiplatelet drug aspirin is considered as a cornerstone in medical treatment of patients with CV or cerebrovascular diseases. Despite its use, a significant number of patients had recurrent adverse ischemic events. Inter-individual variability of platelet aggregation in response to aspirin may be an explanation for some of these events. Multiple trials have linked aspirin resistance to these adverse events.</p></div><div><h3>Objectives</h3><p>The aim of this study was to estimate the prevalence of aspirin resistance among patients with coronary artery disease (CAD) in Egypt and evaluate its impact on clinical outcome.</p></div><div><h3>Methods</h3><p>A total of 50 patients with documented history of CAD were included; they were on aspirin 150<!--> <!-->mg/day for more than seven days and no other antiplatelet drugs. They were evaluated for aspirin resistance using light transmission aggregometry. Aspirin resistance was defined as a mean aggregation of >20% with 0.5<!--> <!-->mg/ml arachidonic acid. They were followed up after six months for cardiac death, unstable angina (UA), myocardial infarction (MI), and stroke.</p></div><div><h3>Results</h3><p>Prevalence of aspirin resistance was 48% in our study group. Aspirin resistance was significantly higher in patients with family history of CAD (<em>p</em> <!-->=<!--> <!-->0.044), smoking (<em>p</em> <!-->=<!--> <!-->0.011), history of MI (<em>p</em> <!-->=<!--> <!-->0.024), history of percutaneous coronary intervention (PCI) (<em>p</em> <!-->=<!--> <!-->0.001), and concomitant NSAIDs intake (<em>p</em> <!-->=<!--> <!-->0.047). Moreover, aspirin resistance was more common among patients with multi-vessel CAD (<em>p</em> <!-->=<!--> <!-->0.024). Aspirin-resistant patients had a significantly higher rate of UA (<em>p</em> <!-->=<!--> <!-->0.001) and all major adverse cardiac events (MACE) (<em>p</em> <!--><<!--> <!-->0.001).</p></div>","PeriodicalId":31233,"journal":{"name":"Egyptian Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejccm.2014.12.001","citationCount":"2","resultStr":"{\"title\":\"Aspirin resistance: Prevalence and clinical outcome in Egypt\",\"authors\":\"Ahmed Salah, Mohammed El-Desuky, Amal Rizk, Amr El-Hadidy\",\"doi\":\"10.1016/j.ejccm.2014.12.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>The antiplatelet drug aspirin is considered as a cornerstone in medical treatment of patients with CV or cerebrovascular diseases. Despite its use, a significant number of patients had recurrent adverse ischemic events. Inter-individual variability of platelet aggregation in response to aspirin may be an explanation for some of these events. Multiple trials have linked aspirin resistance to these adverse events.</p></div><div><h3>Objectives</h3><p>The aim of this study was to estimate the prevalence of aspirin resistance among patients with coronary artery disease (CAD) in Egypt and evaluate its impact on clinical outcome.</p></div><div><h3>Methods</h3><p>A total of 50 patients with documented history of CAD were included; they were on aspirin 150<!--> <!-->mg/day for more than seven days and no other antiplatelet drugs. They were evaluated for aspirin resistance using light transmission aggregometry. Aspirin resistance was defined as a mean aggregation of >20% with 0.5<!--> <!-->mg/ml arachidonic acid. They were followed up after six months for cardiac death, unstable angina (UA), myocardial infarction (MI), and stroke.</p></div><div><h3>Results</h3><p>Prevalence of aspirin resistance was 48% in our study group. Aspirin resistance was significantly higher in patients with family history of CAD (<em>p</em> <!-->=<!--> <!-->0.044), smoking (<em>p</em> <!-->=<!--> <!-->0.011), history of MI (<em>p</em> <!-->=<!--> <!-->0.024), history of percutaneous coronary intervention (PCI) (<em>p</em> <!-->=<!--> <!-->0.001), and concomitant NSAIDs intake (<em>p</em> <!-->=<!--> <!-->0.047). Moreover, aspirin resistance was more common among patients with multi-vessel CAD (<em>p</em> <!-->=<!--> <!-->0.024). Aspirin-resistant patients had a significantly higher rate of UA (<em>p</em> <!-->=<!--> <!-->0.001) and all major adverse cardiac events (MACE) (<em>p</em> <!--><<!--> <!-->0.001).</p></div>\",\"PeriodicalId\":31233,\"journal\":{\"name\":\"Egyptian Journal of Critical Care Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2015-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ejccm.2014.12.001\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Egyptian Journal of Critical Care Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2090730314000309\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Egyptian Journal of Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2090730314000309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
Aspirin resistance: Prevalence and clinical outcome in Egypt
Introduction
The antiplatelet drug aspirin is considered as a cornerstone in medical treatment of patients with CV or cerebrovascular diseases. Despite its use, a significant number of patients had recurrent adverse ischemic events. Inter-individual variability of platelet aggregation in response to aspirin may be an explanation for some of these events. Multiple trials have linked aspirin resistance to these adverse events.
Objectives
The aim of this study was to estimate the prevalence of aspirin resistance among patients with coronary artery disease (CAD) in Egypt and evaluate its impact on clinical outcome.
Methods
A total of 50 patients with documented history of CAD were included; they were on aspirin 150 mg/day for more than seven days and no other antiplatelet drugs. They were evaluated for aspirin resistance using light transmission aggregometry. Aspirin resistance was defined as a mean aggregation of >20% with 0.5 mg/ml arachidonic acid. They were followed up after six months for cardiac death, unstable angina (UA), myocardial infarction (MI), and stroke.
Results
Prevalence of aspirin resistance was 48% in our study group. Aspirin resistance was significantly higher in patients with family history of CAD (p = 0.044), smoking (p = 0.011), history of MI (p = 0.024), history of percutaneous coronary intervention (PCI) (p = 0.001), and concomitant NSAIDs intake (p = 0.047). Moreover, aspirin resistance was more common among patients with multi-vessel CAD (p = 0.024). Aspirin-resistant patients had a significantly higher rate of UA (p = 0.001) and all major adverse cardiac events (MACE) (p < 0.001).
期刊介绍:
The Egyptian Journal of Critical Care Medicine is the official Journal of the Egyptian College of Critical Care Physicians, the most authoritative organization of Egyptian physicians involved in the multi-professional field of critical care medicine. The journal is intended to provide a peer-reviewed source for multidisciplinary coverage of general acute and intensive care medicine and its various subcategories including cardiac, pulmonary, neuro, renal as well as post-operative care. The journal is proud to have an international multi-professional editorial board in the broad field of critical care that will assist in publishing promising research and breakthrough reports that lead to better patients care in life threatening conditions, and bring the reader a quick access to the latest diagnostic and therapeutic approaches in monitoring and management of critically ill patients.